sulforaphane has been researched along with Diabetic Cardiomyopathies in 7 studies
sulforaphane: from Cardaria draba L.
sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.
Diabetic Cardiomyopathies: Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, Y | 1 |
| Zhou, S | 3 |
| Guo, H | 1 |
| Zhang, J | 1 |
| Ma, T | 1 |
| Zheng, Y | 4 |
| Zhang, Z | 5 |
| Cai, L | 7 |
| Xin, Y | 2 |
| Bai, Y | 2 |
| Jiang, X | 1 |
| Wang, Y | 3 |
| Wintergerst, KA | 1 |
| Cui, T | 2 |
| Ji, H | 2 |
| Tan, Y | 5 |
| Wang, J | 1 |
| Wang, S | 4 |
| Wang, W | 1 |
| Chen, J | 3 |
| Zheng, Q | 1 |
| Liu, Q | 1 |
| Yan, X | 1 |
| Mellen, N | 1 |
| Kong, M | 1 |
| Gu, J | 2 |
| Xu, Z | 3 |
| Wintergerst, K | 1 |
| Sun, J | 1 |
| Cheng, Y | 1 |
| Wu, H | 1 |
| Kong, L | 1 |
| Keller, BB | 1 |
| Zhou, H | 1 |
| Cui, W | 1 |
| Miao, X | 1 |
| Barati, MT | 1 |
| Zhang, C | 1 |
| Chen, Q | 1 |
7 other studies available for sulforaphane and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Protective effects of sulforaphane on type 2 diabetes-induced cardiomyopathy via AMPK-mediated activation of lipid metabolic pathways and NRF2 function.
Topics: AMP-Activated Protein Kinases; Animals; Cardiotonic Agents; Diabetes Mellitus, Experimental; Diabete | 2020 |
Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ß/Fyn pathway.
Topics: Angiotensin II; Animals; Diabetic Cardiomyopathies; Disease Models, Animal; Glycogen Synthase Kinase | 2018 |
Protection against diabetic cardiomyopathy is achieved using a combination of sulforaphane and zinc in type 1 diabetic OVE26 mice.
Topics: Animals; Cardiotonic Agents; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Ca | 2019 |
Sulforaphane prevents the development of cardiomyopathy in type 2 diabetic mice probably by reversing oxidative stress-induced inhibition of LKB1/AMPK pathway.
Topics: Adenylate Kinase; AMP-Activated Protein Kinases; Animals; Autophagy; Cardiotonic Agents; Diabetes Me | 2014 |
Broccoli sprout extract prevents diabetic cardiomyopathy via Nrf2 activation in db/db T2DM mice.
Topics: Animals; Brassica; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Gen | 2016 |
Metallothionein Is Downstream of Nrf2 and Partially Mediates Sulforaphane Prevention of Diabetic Cardiomyopathy.
Topics: Animals; Anticarcinogenic Agents; Blotting, Western; Diabetes Mellitus, Experimental; Diabetes Melli | 2017 |
Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation.
Topics: Animals; Catalase; Cell Line; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diab | 2013 |